Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
89Zr-patritumab deruxtecan PET/CT whole-body HER3 quantification in EGFR-mutant NSCLC
2023-508233-14-00Phase 2Authorised
- Sponsor
- Netherlands Cancer Institute
- Start
- Jul 2024
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of patritumab deruxtecan and zirconium-89 patritumab deruxtecan in non-small cell lung cancer (NSCLC), sponsored by Netherlands Cancer Institute. Primary endpoint: Optimal imaging dose of patritumab deruxtecan co-injected with 89Zr-patritumab deruxtecan. Planned start Jul 2024; status: authorised.
02
Drugs
patritumab deruxtecanzirconium-89 patritumab deruxtecan
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2023-508233-14-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-508233-14-00.